Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Novartis $NVS has been noticeably absent from the center ring of PD-1/L1 research, quietly advancing its own checkpoint as an in-house asset to match up with a growing pipeline of cancer therapies.